Key result
ICD-coded ACS admission trends align with biomarker-classified data, reflecting a ~4% annual STEMI decline.
Why the study?
The implications of the evolving myocardial infarction definition relying on cardiac troponin tests on trends of acute coronary syndrome subtypes from routinely collected hospital morbidity data were unclear.
Are ICD-coded hospitalisation rates for acute coronary syndromes concordant with biomarker-classified admission rates?
Observational (n=30,683)
Yes
Are ICD-coded hospitalisation rates for acute coronary syndromes concordant with biomarker-classified admission rates?
Administrative ICD-coded data is a valid tool for monitoring population trends in ACS subtypes, as it accurately reflects biomarker-classified admission rates in the troponin era.
Supports ICD-coded data for ACS surveillance; extends validation of administrative coding against biomarkers but remains observational.
BACKGROUND: Since 2000, the definition of myocardial infarction (MI) has evolved with reliance on cardiac troponin (cTn) tests. The implications of this change on trends of acute coronary syndrome (ACS) subtypes obtained from routinely collected hospital morbidity data are unclear. Using person-linked hospitalisation data, we compared International Classification of Diseases (ICD)-coded data with biomarker-classified admission rates for ST-segment elevation MI (STEMI), non-STEMI (NSTEMI) and unstable angina (UA) in Western Australia (WA). METHODS: We used linked hospitalisation data from all WA tertiary hospitals to identify patients with a principal diagnosis of STEMI, NSTEMI or UA between 2002 and 2016. Linked biomarker results were classified as 'diagnostic' for MI according to established criteria. We calculated age-standardised and sex-standardised rates (ASSRs) for ICD-coded versus biomarker-classified admissions by ACS subtypes and estimated annual change in admissions using Poisson regression adjusting for age and sex. RESULTS: There were 37 272 ACS admissions in 30 683 patients (64.2% male), and 96% of cases had linked biomarker data, predominantly conventional cTn at the start and high-sensitive cTn from late 2013. Despite lower ASSRs, trends in MI classified with a diagnostic biomarker were concordant with ICD-coded admissions rates for both STEMI and NSTEMI. Between 2002 and 2010, STEMI rates declined by 4.1% (95% CI 5.0%, 3.1%) and 3.4% (95% CI 4.6%, 2.3%) in ICD-coded and biomarker-classified admissions, respectively, and both plateaued thereafter. For NSTEMI between 2002 and 2010, the ICD-coded and biomarker-classified rates increased 8.0% per year (95% CI 7.2%, 8.9%) and 8.0% (95% CI 7.0%, 9.0%), respectively, and both subsequently declined. For UA, both ICD-coded and biomarker-classified UA admission rates declined in a steady and concordant manner between 2002 and 2016. CONCLUSIONS: The present study supports the validity of using administrative data to monitor population trends in ACS subtypes as they appear to generally reflect the redefinition of MI in the troponin era.
No takes yet. Share an insight, caveat, or question.
Zemedikun et al. (2024) conducted an observational in Acute coronary syndromes (n=30,683). ICD-coded hospitalisation data vs. Biomarker-classified hospitalisation data was evaluated on Annual change in admission rates for ACS subtypes. ICD-coded admission trends for ACS subtypes were concordant with biomarker-classified trends, demonstrating a 4.1% vs 3.4% annual decline in STEMI rates between 2002 and 2010.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: